NCT05931328
The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.
StatusUnknown
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Jun 2023); last known: Recruiting
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Overall Response Rate (ORR)
Timeframe: Baseline up to 2 years.
Adverse event rate
Timeframe: Baseline up to 3 years.
Secondary (3)
2-year Progression-free Survival (PFS) rate
2-year Overall Survival(OS)rate
Duration of Response(DOR)
Arms and interventions
thiotepa+pomalidomideExperimental
thiotepa combined with pomalidomide: thiotepa 30mg/m2,intravenously guttae, on day 1; pomalidomide 12mg orally daily for 2 weeks. A chemotherapy cycle lasts for 3 weeks.
Drugs: thiotepa combined with pomalidomide
Sites
1 site in 1 country
- Jiangsu Province People's Hospital.Nanjing, Jiangsu, China